The Limited Times

Now you can see non-English news...

New Covid vaccines will be more effective against Omicron


Pfizer/BioNTech and Moderna have successfully tested products that protect against two strains of Sars-CoV-2.

At a time when Covid infections are on the rise again in France (894 cases per 100,000 inhabitants in a rolling week according to the latest figures from Public Health France), the first announcements on the performance of RNA vaccines adapted to the Omicron variant are rather reassuring.

But the meteoric rise of the BA.4 and BA.5 sub-lineages, responsible for most of the current epidemic waves, and the stalemate of the pandemic are already questioning their relevance.

The pharmaceutical groups behind the RNA vaccines - the duo Pfizer/BioNTech and Moderna - have each reported a significant improvement in the effectiveness of their new versions adapted to the Omicron variant, which is still being tested.

The Pfizer/BioNTech duo is developing two products: one, monovalent, specifically targeting Omicron BA.1, which hit France at the very beginning of the year.

Ongoing phase 2/3 trials in patients aged 56 and over show that it can increase the…

This article is for subscribers only.

You have 78% left to discover.

Pushing back the limits of science is also freedom.

Keep reading your article for €0.99 for the first month


Already subscribed?


Source: lefigaro

All tech articles on 2022-07-04

You may like

Trends 24h


© Communities 2019 - Privacy